Drug Profile
Docosahexaenoic acid - Micelle BioPharma
Alternative Names: Altemia; Doconexent; SC-411Latest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Sancilio & Company
- Class Antihyperlipidaemics; Docosahexaenoic acids; Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 18 Oct 2021 No development reported - Phase-III for Sickle cell anaemia (In adolescents, In children) in USA (PO)
- 01 Feb 2019 Micelle BioPharma plans a phase III trial for Sickle cell anaemia in March 2019 (NCT02604368)
- 30 Apr 2018 Additional safety and efficacy data from the phase II SCOT trial were released by Sancilio Pharmaceuticals